CLINICAL TECHNOLOGIES

Technology Matrix

Frontier oncology technologies already accessible in China — from proton & heavy-ion therapy to solid-tumor CAR-T, BNCT and ADC therapeutics.

Showing 9 of 11

Cellular Therapy

CAR-T Cell Therapy

China has 7 NMPA-approved CAR-T products (Yescarta-CN, Relma-cel, FKC876/Equecabtagene, etc.), including the world’s first fully human BCMA CAR-T. China leads globally in CAR-T trial volume at roughly 1/3-1/5 of Western costs.

LymphomaLeukemia

NMPA-approved · Multi-layer payment coverageView details

Particle Therapy

Proton & Carbon-Ion Therapy

Shanghai Proton and Heavy Ion Center — China’s first dual-modality particle center and the world’s first heavy-ion center to exceed 1,000 patients/year; 10,000+ patients treated, overall 5-year survival 70.4%, 93.8% for primary nasopharyngeal cancer, 97.2% for localized prostate cancer.

Nasopharyngeal cancerProstate cancerBrain tumorLung cancer

Mature clinical use · approx. RMB 310,000 avg.View details

Particle Therapy

Boron Neutron Capture Therapy

Xiamen Humanity Hospital hosts China’s first and the world’s largest accelerator-based BNCT center with the domestically developed system (neutron flux 1.1×10⁹ n·cm⁻²·s⁻¹, <30 min per session). Known as the "fifth cancer therapy", a course takes only 1-2 sessions.

Nasopharyngeal cancerBrain tumorSarcoma

Drug-device registration trials (Phase I closing)View details

Cellular Therapy

Solid-Tumor Cell Therapy (TCR-T / TIL / CAR-T)

China leads globally in solid-tumor cell therapy trials; the Claudin18.2-targeting CAR-T is the world’s first CAR-T approved for a solid tumor (gastric/GEJ adenocarcinoma). Next-gen TCR-T and TIL programs run at national cancer centers.

Gastric cancerSarcomaLiver cancerLung cancer

Partially approved · Rapidly advancing trialsView details

Innovative Drugs

China-Originated Targeted Drugs

Zanubrutinib (BeOne) — the first China-originated cancer drug approved by the FDA, superior to ibrutinib in head-to-head trials, with 2024 global sales of RMB 18.86B. Fruquintinib is the first China-originated oncology drug approved in the US, EU and Japan, available in 30+ countries.

LymphomaColorectal cancerLung cancer

FDA / NMPA / EMA approvedView details

Innovative Drugs

China-Originated Immunotherapy (PD-1 / Bispecifics)

Toripalimab — the first China-made PD-1 approved by the FDA (nasopharyngeal carcinoma); tislelizumab FDA-approved for ESCC; cadonilimab is the world’s first approved PD-1/CTLA-4 bispecific antibody; penpulimab FDA-approved in 2025.

Nasopharyngeal cancerEsophageal cancerLung cancerGastric cancer

FDA / NMPA approved · Significantly lower costView details

Advanced Equipment

Precision Imaging (United Imaging uEXPLORER)

United Imaging’s uEXPLORER is the world’s first total-body PET-CT, enabling single-bed whole-body dynamic imaging with ~40x higher sensitivity for earlier detection of micro-metastases. The uMR Jupiter is the world’s first whole-body 5.0T MRI. Chinese high-end imaging systems are exported to the US, EU and Japan.

Lung cancerLymphomaColorectal cancerProstate cancer

Installed at national cancer centersView details

Surgical Oncology

Robotic Surgical Oncology (da Vinci / Toumai)

da Vinci radical surgeries are routine at national cancer centers; the domestically developed Toumai four-arm laparoscopic robot is NMPA-approved and commercially exported, delivering sub-millimeter precision in prostate, hepatobiliary and GI cancer surgery.

Prostate cancerLiver cancerGastric cancerColorectal cancer

Mature use · Domestic robot NMPA-approvedView details

Cellular Therapy · Novel Drug

Solid-Tumor CAR-T (CT041 / Kailimei)

Carsgen’s Kailimei (Claudin18.2-targeted CAR-T) is the world’s first approved solid-tumor CAR-T, indicated for Claudin18.2-positive gastric/GEJ adenocarcinoma — extending cellular therapy from blood cancers into solid tumors.

Gastric cancerPancreatic cancer

World-first solid-tumor CAR-T approved (NMPA)View details

Request Case Review

Share your contact details, confirmed diagnosis and main question. No medical files needed at this stage. A clinical coordinator will contact you within 24-48 hours.

Book a Consultation

Free case review